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Fever in neutropenia (FN) is the most frequent potentially life threatening complication of chemotherapy
for cancer. Prediction of the risk to develop FN during chemotherapy would allow for targeted prophylaxis.
This retrospective, single centre cohort study in pediatric patients diagnosed with cancer before 17 years
covered two decades, 1993 to 2012. The 583 (73%) of 800 patients diagnosed with cancer who had
received chemotherapy were studied here. Data on 2113 observation periods was collected, deﬁned by
stable combinations of 11 predeﬁned characteristics potentially associated with FN. They covered 692 years
of cumulative chemotherapy exposure time, during which 712 FN episodes were diagnosed, 154 (22%) of
them with bacteremia. The risk to develop FN and FN with bacteremia remained stable over time. These
data can mainly be used to study FN risks over time and between centers, and to derive or externally
validate FN risk prediction rules.
Design Type(s) data integration objective • observation design
Measurement Type(s) clinical history
Technology Type(s) medical data
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Sample Characteristic(s) Homo sapiens
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Background and Summary
Fever in neutropenia (FN) is the most frequent potentially life-threatening complication of chemotherapy
in children and adolescents with cancer1. About half of the children treated with chemotherapy for cancer
develop at least one FN episode2,3. To reduce the risk to develop FN during chemotherapy, non-
pharmacological measures, prophylactic antibiotics, and granulocyte colony-stimulating factor can be
applied prophylactically4,5. The current standard therapy for FN includes emergency hospitalisation and
empirical administration of intravenous broad-spectrum antibiotics6. This approach reduced FN
mortality from around 30% in the 1970s to around 1% in the late 1990s (ref. 7).
Both prophylactic and therapeutic FN directed measures generate relevant costs, can stimulate
bacterial resistance and can lead to decreased quality of life for patients and their families5,6,8. Efﬁcient
risk prediction might reduce these drawbacks. Considerable evidence has been published on the
prediction of different outcomes in patients diagnosed with FN. Correspondingly, risk adapted FN
therapy based on validated risk prediction rules is currently ﬁnding its way into routine management in
pediatric oncology6,9–14. In contrast, there is only scarce and non-validated evidence how to predict the
risk to develop FN during chemotherapy15. Prophylaxis is usually restricted to patients with acute
myeloid leukemia5,16. Risk-adapted and thus targeted FN prophylaxis is far from clinical routine in the
majority of patients15.
This study in children and adolescents treated with chemotherapy for cancer aimed to collect long-
term data on 11 predeﬁned patient- and treatment-related characteristics potentially associated with FN,
on FN itself, and on the speciﬁcally relevant subgroup of FN with bacteremia. The main clinical
motivation of this study was to generate data for the development of rules predicting the risk of FN
during chemotherapy in pediatric patients with cancer, ﬁnally leading to evidence-based targeted
prophylaxis in these patients.
This study was designed as a retrospective, single centre cohort study in pediatric patients diagnosed
with cancer before 17 years, covering two decades, 1993 to 2012. All clinical information was directly
extracted from patient charts.
In total, 800 patients were found who had been diagnosed with cancer below the age of 17 years in
Bern from 1993 to 2012. Of these, 596 (75%) were reported to have received chemotherapy. Charts were
not accessible in 13 (2.2%). The remaining 583 (98%) patients were studied here (Figure 1). The slight
preponderance of male patients (327, 56%), the distribution of age at diagnosis, and the distribution of
diagnoses were all compatible with the known distributions of pediatric patients with cancer in developed
countries.
A total of 2,113 observation periods, deﬁned by a constant combination of the 11 characteristics, were
found (median per patient, 3; range, 1 to 18; interquartile range (IQR), 2 to 5) (File data.17B.
ObservationPeriods.csv. Data Citation 1). Their median duration was 64 days (range, 1 to 866; IQR, 25 to
157), with a cumulative duration of 252,724 days (692 years) chemotherapy exposure time (CET).
During the cumulative CET of 692 years, 846 FN episodes were known to be clinically diagnosed (rate,
1.22 per year; exact 95% conﬁdence interval (CI), 1.14 to 1.31). Criteria of FN were not ascertainable in 43
(5%) of these episodes, and were not fulﬁlled in 91 (11%). The remaining 712 FN episodes (84%) were
studied here (rate, 1.03 per year of CET; exact 95% CI, 0.95 to 1.11).
At least one FN episode was recorded in 294 (50%) of the 583 patients (median, 1; range, 0 to 9; IQR, 0
to 2). Bacteremia was detected in 154 (22%) of the 712 FN episodes in 111 (19%) patients. Over the time
Reported from Swiss Childhood Cancer Registry (n=797) 
Additional patients from institutional lists (n=3) 
Patients with cancer (n=800) 
Patients excluded (n=217) 
- No chemotherapy received (n=204) 
- Charts not accessible (n=13) 
Patients studied here (n=583) 
Patients
Figure 1. Patients ﬂowsheet.
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studied, the risk to develop FN (rate ratio per decade, 0.97; exact 95% CI 0.72 to 1.30; p= 0.83, results of
mixed Poisson regression) and FN with bacteremia (rate ratio per decade, 0.88; exact 95% CI, 0.38 to 2.04;
p= 0.76) did not change signiﬁcantly.
These data can mainly be used (1) to study the risk to develop FN during chemotherapy over time and
between centers; (2) to derive risk prediction rules for FN, and for FN with bacteremia; (3) to derive
corresponding clinical decision rules for risk-adapted, targeted FN prophylaxis during chemotherapy; and
(4) to externally validate corresponding rules derived from other datasets.
Methods
Study design
A retrospective, single site cohort study covering two decades, from 1993 to 2012, was performed at the
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, Bern University
Hospital, University of Bern, Switzerland.
This study was approved by the Institutional Review Board (Direktion Lehre und Forschung,
Inselspital Bern; registration number, 13-06-11; last update, April 02, 2014), including waiver of informed
consent. On June 30, 2014, data were fully anonymised before analysis, in order to comply with the
requests of the new Swiss Federal Law on Human Research.
Patients and their clinical management
A clinically useful extended cancer deﬁnition was used that included leukemia, lymphoma, malignant
solid tumors, benign tumors of the central nervous system, and Langerhans cell histiocytosis17. All
children and adolescents diagnosed with cancer and treated with chemotherapy were eligible. Age at
diagnosis of malignancy and of FN episodes was restricted to ≤17 years. Patients were primarily
identiﬁed via the Swiss Childhood Cancer Registry17. In order to reduce recruitment bias, information on
patients was complemented using clinically used patients lists for the entire period, and patient lists from
earlier research projects for a part of the period covered here3,15,18–20. Information on the characteristics
of the patients studied, at start of study for the individual patients, is published (File data.17B.
ObservationPeriods.csv. Data Citation 1).
Most patients were treated for their cancer according to established international protocols. Clinical
management regarding prophylaxis and treatment of FN essentially remained unchanged during the
entire study period: Patients did not receive any antibiotic prophylaxis beyond prophylaxis against
Pneumocystis jiroveci pneumonia with oral trimethoprim / sulfamethoxazole, which was replaced by
inhaled pentacarinate in selected patients15. Daily subcutaneous granulocyte colony-stimulating factor
(G-CSF) was applied if requested by protocol15.
Data collection
Information on chemotherapy, on FN episodes, on the detection of bacteremia in FN, and on 11 clinical
characteristics potentially associated with FN was retrospectively extracted from patient charts as
described15. Three of these 11 characteristics were patient related (gender, age at diagnosis, year of
diagnosis), two were disease related (diagnostic group, relapse status), and six were related to therapy and
course of disease (chemotherapy intensity, presence of central venous access device (CVAD), bone
marrow involvement with ≥5% leukemic cells or any detectable malignant cells in solid tumors, time after
diagnosis, prior episodes of FN, prior episodes of FN with bacteremia).
Observation periods
The CET was deﬁned as the cumulative duration of chemotherapy plus 3 weeks accounting for
neutropenia developing after cessation of chemotherapy. The CET in a speciﬁc patient was split into a
non-predeﬁned number of observation periods. They were deﬁned by a constant combination of the 11
characteristics potentially associated with the risk to develop FN described above. By deﬁnition, 8 of these
11 characteristics (2 disease related and 6 related to therapy and course of disease) can change over time.
As an example, the induction therapy of a patient with newly diagnosed acute lymphoblastic leukemia is
usually split into at least three observation periods: The ﬁrst is characterized by the presence of bone
marrow involvement, by deﬁnition, and the absence of a CVAD. The second starts on the day after
insertion of a CVAD and is characterized by continued bone marrow involvement and the presence of a
CVAD. The third starts on the day after diagnosis of remission and is characterized by the absence of
bone marrow involvement with continued presence of a CVAD. Correspondingly, multiple observation
periods were deﬁned in the vast majority of patients. This allows for future analysis of associations of
characteristics with FN, and FN with bacteremia. Information on the observation periods studied is
published (File data.17B.ObservationPeriods.csv. Data Citation 1).
Given that for nearly all patients more than one observation period was recorded, that the length of
these observation periods varies importantly, and that more than one FN episode can be recorded in one
observation period, mixed Poisson regression seems to be an adequate type of analysis for these data,
while time-to-event based analyses are not.
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Fever in neutropenia
An episode of FN was deﬁned as fever in a patient with severe chemotherapy-induced neutropenia. Until
July 8, 2007, fever was deﬁned as an axillary temperature ≥38.5 °C persisting ≥2 h, or a single
temperature ≥39.0 °C. Starting July 9, 2007, the temperature measurement method was changed from
axillary to infrared tympanic thermometry, and the rule deﬁning fever was simpliﬁed to a single tympanic
temperature ≥39.0 °C19 for clinical reasons. In the setting of rising temperatures, the different limits used
for the different measurement methods have been shown to be comparable21. Severe neutropenia was
always deﬁned as an absolute neutrophil count o0.5 G/L22. Multiple FN episodes per patient were
allowed. All FN episodes fulﬁlling these criteria, even if fever occurred after interventions like transfusion
of blood products or after cytarabine treatment, were included. However, episodes of FN additionally
diagnosed for clinical reasons at lower temperatures and/or with an absolute neutrophil count ≥0.5G/L
were not studied here23. Bacteremia was deﬁned as the detection of any bacteria in any blood culture
from the beginning until the end of the FN episode.
Emergency hospitalization and empirical broad-spectrum intravenous antimicrobial therapy, usually
ceftriaxone plus amikacin, were routinely applied. Children were discharged and antibiotics were usually
stopped if children were afebrile and well for 48 h, if there was no evidence for severe bacterial infection,
and if there were any signs of bone marrow reconstitution18.
The beginning of an FN episode was deﬁned as the time point when the FN criteria were fulﬁlled. The
end of this episode was deﬁned as the time point when antibiotics were stopped, the patient was
discharged, or chemotherapy was restarted, whichever occurred earlier. If the FN criteria were fulﬁlled
again after this time point, this counted as a further FN episode. Correspondingly, multiple FN episodes
per observation period were possible. Taken together with the stopping criteria mentioned above, FN
episodes could thus end despite continued neutropenia, and second FN episodes could be diagnosed
within one episode of neutropenia.
Data classiﬁcation
Chemotherapy was classiﬁed into 4 levels of myelosuppressive intensity according to the expected
duration of severe neutropenia as described15,18, which is an extension of an earlier model using only 2
levels24 (Table 1). This classiﬁcation does not cover the additional risk of infection due to new therapeutic
agents like rituximab that do not lead to relevant neutropenia.
In order to comply with the full anonymization mentioned above, age at diagnosis was split into 4
categories covering 4 years each (o4 years, 4 to 7.99 years, 8 to 11.99 years, and ≥12 years), and the time
of observation was split into 5 periods of 4 years each (1993 to 1996, 1997 to 2000, 2001 to 2004, 2005 to
2008, and 2009 to 2012).
Data Records
A single data records resulted from this study. It contains information on the 2,113 observation periods
studied in these 583 patients (File data.17B.ObservationPeriods.csv. Data Citation 1) (Table 2).
Information on patients at time of study entry can be extracted from this ﬁle by selecting the ﬁrst
observation period per patient (LINE.PER.PAT= 1).
Detailed information on variable speciﬁcations is included in a readme ﬁle (File data.17B.ReadMe.csv.
Data Citation 1).
Technical Validation
Reduction of recruitment bias
Patients were primarily identiﬁed via the Swiss Childhood Cancer Registry17. In order to reduce
recruitment bias, information on patients was complemented by clinically used institutional patients lists
for the entire period, and patient lists from earlier research projects for a part of the period covered
here3,15,18–20 (Figure 1).
Increasing reliability of information on FN episodes
A simple restricted deﬁnition of FN episodes, based on veriﬁable quantitative information both on fever
and on neutropenia was used. Correspondingly, FN episodes additionally diagnosed clinically when fever
Level Intensity Expected duration of severe neutropenia
1 Minimally myelosuppressive None expected
2 Brieﬂy myelosuppressive ≤ 10 days
3 Strongly myelosuppressive >10 days
4 Myeloablative Hematopoietic stem cell recovery required
Table 1. Myelosuppressive intensity of chemotherapy.Modiﬁed from refs 15 and 18, plus ref. 23 regarding
the distinction of level 2 versus 3.
www.nature.com/sdata/
SCIENTIFIC DATA | 5:180038 | DOI: 10.1038/sdata.2018.38 4
and or neutropenia limits had not been reached23, or when these limits were not ascertainable, were
excluded.
A simple deﬁnition of bacteremia was used as well, without the need of partly subjective judgment if
detection of a common commensal in a blood culture should be considered as infection, i.e., bacteremia,
or contamination.
In case of inconsistencies or of unclear information found in the charts, an experienced pediatric
haematologist-oncologist (RAA) consulted patient charts again and resolved these questions.
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Observations Time covered Center Data source Data
Patients 1993 to 2012a Berna Swiss Childhood Cancer Registry17
Institutional patient lists
data.17B. ObservationPeriods.csv [LINE.PER.PAT= 1]
Observation Periods 1993 to 2012a Berna Chart records data.17B.ObservationPeriods.csv
Table 2. Overview. aIdentical for both patients and observation periods.
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